Purpose: This systematic review evaluated the clinical utility of single photon emission computed tomography (SPECT) in traumatic brain injury (TBI).

Methods: After defining a PICO Statement (Population, Intervention, Comparison and Outcome Statement), PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria were applied to identify 1600 articles. After screening, 374 articles were eligible for review. Inclusion for review was focus on SPECT in the setting of mild, moderate, or severe TBI with cerebral lobar specificity of SPECT findings. Other inclusion criteria were comparison modalities in the same subjects and articles in English. Foreign language articles, SPECT studies that did not include comparison modalities, and case reports were not included for review.

Results: We identified 19 longitudinal and 52 cross-sectional studies meeting inclusion criteria. Three longitudinal studies examined diagnostic predictive value. The first showed positive predictive value increases from initial SPECT scan shortly after trauma to one year follow up scans, from 59% to 95%. Subsequent work replicated these results in a larger cohort. Longitudinal and cross sectional studies demonstrated SPECT lesion localization not detected by CT or MRI. The most commonly abnormal regions revealed by SPECT in cross-sectional studies were frontal (94%) and temporal (77%) lobes. SPECT was found to outperform both CT and MRI in both acute and chronic imaging of TBI, particularly mild TBI. It was also found to have a near 100% negative predictive value.

Conclusions: This review demonstrates Level IIA evidence (at least one non-randomized controlled trial) for the value of SPECT in TBI. Given its advantages over CT and MRI in the detection of mild TBI in numerous studies of adequate quality, and given its excellent negative predictive value, it may be an important second test in settings where CT or MRI are negative after a closed head injury with post-injury neurological or psychiatric symptoms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960124PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091088PLOS

Publication Analysis

Top Keywords

spect
10
clinical utility
8
traumatic brain
8
brain injury
8
systematic review
8
inclusion criteria
8
comparison modalities
8
cross-sectional studies
8
mild tbi
8
negative predictive
8

Similar Publications

Background: In Japan, the number of patients with dementia is increasing and there is a shortage of human resources who can conduct detailed psychological examinations, and the development and implementation of new tools is essential for improving dementia care. Japan is one of seven sites across the globe focusing on healthcare system preparedness as part of the Davos Alzheimer's Collaborative Early Detection flagship program. As part of this program, Japan implemented new tools including a digital cognitive assessment (DCA) and blood-based biomarker (BBM) to increase rates of early detection of cognitive impairment.

View Article and Find Full Text PDF

False-Positive Uptake of 123I-MIBG in the Basal Ganglion in a Pediatric Neuroblastoma Patient.

Clin Nucl Med

January 2025

From the Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

A 7-year-old boy with high-risk neuroblastoma underwent 123I-MIBG SPECT/CT to evaluate the therapy response. The scan revealed abnormal 123I-MIBG uptake in the left basal ganglion, indicating the possibility of brain metastasis. Subsequent contrast-enhanced brain MRI, however, did not show any abnormal signal intensity in the left basal ganglion.

View Article and Find Full Text PDF

Breast cancer presents a significant global health challenge, necessitating continued innovation in diagnostic and therapeutic approaches. Recent advances have led to the identification of cancer-associated fibroblasts, which are highly prevalent in breast cancers and express fibroblast activation proteins (FAPs), as critical targets. FAP-specific radiotracers, when used with PET/CT and SPECT/CT, have significant potential for improving early breast cancer detection, staging, treatment response monitoring, and therapeutic intervention.

View Article and Find Full Text PDF

Development of Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging.

Mol Pharm

January 2025

Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.

As an enzyme that plays an important role in DNA repair, poly(ADP-ribose) polymerase-1 (PARP-1) has become a popular target for cancer therapy. Nuclear medicine molecular imaging technology, supplemented by radiolabeled PARP-1 inhibitors, can accurately determine the expression level of PARP-1 at lesion sites to help patients choose an appropriate treatment plan. In this work, niraparib was modified with a hydrazinonicotinamide (HYNIC) group to generate the ligand NPBHYNIC, which has an affinity (IC) of 450.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!